Sage Therapeutics Announces Brexanolone Achieves Primary Endpoints in Both Phase 3 Clinical Trials in Postpartum Depression

Chardan Capital Markets Upgrades Sage Therapeutics (SAGE) to Buy

Chardan Capital Markets upgraded Sage Therapeutics (NASDAQ: SAGE) from Neutral to Buy with a price target of $140.00 following phase III Hummingbird data for brexanolone in PPD.

Analyst Gbola Amusa see a read-across from brexanolone in PPD to other vast-market indications, like MDD, Sage... More

Sage Therapeutics (SAGE) PT Raised to $135 at Cowen

Cowen raised its price target on Sage Therapeutics (NASDAQ: SAGE) to $135.00 (from $90.00) while maintaining a Outperform rating following positive top-line data from the Ph3 HUMMINGBIRD trials of brexanolone in moderate and severe PPD.

Analyst Ritu Baral is optimistic that... More

Sage Therapeutics (SAGE) PT Raised to $105 at Stifel

Stifel raised its price target on Sage Therapeutics (NASDAQ: SAGE) to $105.00 (from $91.00) while maintaining a Buy rating after the company reported positive top-line data from P3 Hummingbird trials with brexanolone (i.v. formulation) in postpartum depression (PPD).

Analyst Adam Walsh this... More

Sage Therapeutics (SAGE) PT Raised to $123 at Leerink Partners

Leerink Partners analyst Paul Matteis raised its price target on Sage Therapeutics (NASDAQ: SAGE) to $123.00 (from $85.00) while maintaining an Outperform rating.

Sage Therapeutics (SAGE) PT Raised to $100 at Needham & Company

Needham & Company raised its price target on Sage Therapeutics (NASDAQ: SAGE) to $100.00 (from $86.00) while maintaining a Buy rating after both IV brexanolone Phase 3 trials in moderate and severe postpartum depression (PPD) hit on the primary efficacy endpoint.

Danielle Brill said it... More

Sage Therapeutics (SAGE) Hits 'Very Significant Milestone' - BMO

BMO Capital analyst Gary Nachman reiterated an Outperform rating and $80 price target on Sage Therapeutics (NASDAQ: SAGE) hit its most important milestone as a company to date with very positive data for Brexanolone in two Phase 3 studies in post-partum depression.

Nachman said... More

SAGE Therapeutics (SAGE) Climbs 50% After Phase 3 Study to Treat Postpartum Depression Meets Primary Endpoint

SAGE Therapeutics (NASDAQ: SAGE) Climbs 50% After Phase 3 Study to Treat Postpartum Depression Meets Primary Endpoint

LINK